Komori
K Pharma (4896) · FactIncrease year on year

R&D investment in the drug discovery and regenerative medicine pipeline

First written in FY2023-Q3. . Latest entry: FY2026-H1.

8entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2023-Q3 – FY2026-H12023: 120232024: 320242025: 220252026: 22026
Same theme, other companies
R&D Investment in Drug Discovery and Regenerative Medicine PipelinesA theme 11 companies write about · 3 as a headwind · 9 as a tailwind

The whole theme swung hardest in 2022: 1 of 8 companies on the "Worse" side.

3 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1Increase year on yearAnnual report

    「Research and development activities during the current interim accounting period amounted to ¥206.764 million.」

    Research and development expenses were ¥206.764 million, up ¥18.507 million from ¥188.257 million in the prior-year period.
  2. FY2025Year-on-Year DeclineAnnual report

    「Total research and development expenses for the fiscal year were ¥414.525 million.」

    Research and development expenses were ¥414.525 million, down from ¥451.642 million in the previous year.
  3. FY2025-H1Year-on-Year DeclineAnnual report

    「Research and development activities during the current interim accounting period amounted to ¥188.257 million.」

    Research and development expenses were ¥188.257 million, down ¥48.533 million from ¥236.790 million in the prior-year period.
  4. FY2024Increase year on yearAnnual report

    「Total research and development expenses for the fiscal year were ¥451.642 million.」

    Research and development expenses were ¥451.642 million, an increase of ¥196.224 million from ¥255.417 million in the previous year.
  5. FY2024-H1Increase year on yearAnnual report

    「Research and development activities during the current interim accounting period amounted to ¥236.790 million.」

    Research and development expenses were ¥236.790 million in the current interim accounting period, up from ¥106.710 million in the prior-year period.
  6. FY2024-Q1Quarterly research and development expensesAnnual report

    「Research and development activities during the cumulative first-quarter period amounted to ¥148.604 million.」

    The company disclosed research and development activities of ¥148.604 million for the cumulative first-quarter period.
  7. FY2023Increase for the full yearAnnual report

    「Total research and development expenses for the fiscal year were ¥255.417 million.」

    Full-year research and development expenses were ¥255.417 million, up from ¥163.971 million in the previous fiscal year.
  8. FY2023-Q3First statedAnnual report

    「Research and development activities during the cumulative third-quarter period amounted to ¥174.575 million.」

    The company disclosed research and development activities of ¥174.575 million for the cumulative third-quarter period.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for K Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
R&D investment in the drug discovery and regenerative medicine pipeline | K Pharma,Inc. (4896) | Komori